Carlos W. Bertoncini

Carlos W. Bertoncini

Auto-generated profile, based on publicly available information

Carlos W. Bertoncini

Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Cell
Verified
Journal Article
Open access
NCNunilo Cremades
Nunilo Cremades
SCSamuel I.A. Cohen
Samuel I.A. Cohen
EDEmma Deas
Emma Deas
AAANDREY Abramov
ANDREY Abramov
ACAllen Y. Chen
Allen Y. Chen
DKDavid Klenerman
David Klenerman
Here, we use single-molecule techniques to study the aggregation of α-synuclein, the protein whose misfolding and deposition is associated with Parkinson's disease. We identify a conformational change from the initially formed oligomers to stable, more compact proteinase-K-resistant oligomers as the key step that leads ultimately to fibril formation. The oligomers formed as a result of the structural conversion generate much higher levels of oxidative stress in rat primary neurons than do the oligomers formed initially, showing that they are more damaging to cells. The structural conversion is remarkably slow, indicating a high kinetic barrier for the conversion and suggesting that there is a significant period of time for the cellular protective machinery to operate and potentially for therapeutic intervention, prior to the onset of cellular damage. In the absence of added soluble protein, the assembly process is reversed and fibrils disaggregate to form stable oligomers, hence acting as a source of cytotoxic species.

25 January 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CBCarlos W. Bertoncini
Carlos W. Bertoncini
YJYoung-Sang Jung
Young-Sang Jung
CFClaudio O. Fernandez
Claudio O. Fernandez
WHWolfgang Hoyer
Wolfgang Hoyer
CGChristian Griesinger
Christian Griesinger
MZMarkus Zweckstetter
Markus Zweckstetter
In idiopathic Parkinson's disease, intracytoplasmic neuronal inclusions (Lewy bodies) containing aggregates of the protein α-synuclein (αS) are deposited in the pigmented nuclei of the brainstem. The mechanisms underlying the structural transition of innocuous, presumably natively unfolded, αS to neurotoxic forms are largely unknown. Using paramagnetic relaxation enhancement and NMR dipolar couplings, we show that monomeric αS assumes conformations that are stabilized by long-range interactions and act to inhibit oligomerization and aggregation. The autoinhibitory conformations fluctuate in the range of nanoseconds to micro-seconds corresponding to the time scale of secondary structure formation during folding. Polyamine binding and/or temperature increase, conditions that induce aggregation in vitro , release this inherent tertiary structure, leading to a completely unfolded conformation that associates readily. Stabilization of the native, autoinhibitory structure of αS constitutes a potential strategy for reducing or inhibiting oligomerization and aggregation in Parkinson's disease.

14 March 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RRRodolfo M. Rasia
Rodolfo M. Rasia
CBCarlos W. Bertoncini
Carlos W. Bertoncini
DMDerek Marsh
Derek Marsh
WHWolfgang Hoyer
Wolfgang Hoyer
DCDmitry Cherny
Dmitry Cherny
CFClaudio O. Fernandez
Claudio O. Fernandez
The aggregation of α-synuclein (AS) is characteristic of Parkinson's disease and other neurodegenerative synucleinopathies. We demonstrate here that Cu(II) ions are effective in accelerating AS aggregation at physiologically relevant concentrations without altering the resultant fibrillar structures. By using numerous spectroscopic techniques (absorption, CD, EPR, and NMR), we have located the primary binding for Cu(II) to a specific site in the N terminus, involving His-50 as the anchoring residue and other nitrogen/oxygen donor atoms in a square planar or distorted tetragonal geometry. The carboxylate-rich C terminus, originally thought to drive copper binding, is able to coordinate a second Cu(II) equivalent, albeit with a 300-fold reduced affinity. The NMR analysis of AS–Cu(II) complexes reveals the existence of conformational restrictions in the native state of the protein. The metallobiology of Cu(II) in Parkinson's disease is discussed by a comparative analysis with other Cu(II)-binding proteins involved in neurodegenerative disorders.

12 July 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ABAndres Binolfi
Andres Binolfi
RRRodolfo M. Rasia
Rodolfo M. Rasia
CBCarlos W. Bertoncini
Carlos W. Bertoncini
MCMarcelo Ceolin
Marcelo Ceolin
MZMarkus Zweckstetter
Markus Zweckstetter
CFClaudio O. Fernandez
Claudio O. Fernandez

1 December 2005 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
Pau BernadoPau Bernado
Pau Bernado
CBCarlos W. Bertoncini
Carlos W. Bertoncini
CGChristian Griesinger
Christian Griesinger
MZMarkus Zweckstetter
Markus Zweckstetter
MBMartin Blackledge
Martin Blackledge

1 September 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CBCarlos W. Bertoncini
Carlos W. Bertoncini
CFClaudio O. Fernandez
Claudio O. Fernandez
CGChristian Griesinger
Christian Griesinger
TJThomas M. Jovin
Thomas M. Jovin
MZMarkus Zweckstetter
Markus Zweckstetter
A30P and A53T mutations of the presynaptic proteinα-synuclein are associated with familial forms of Parkinson disease. NMR spectroscopy demonstrates that Parkinsonism-linked mutations greatly perturb specific tertiary interactions essential for the native state of α-synuclein. However, α-synuclein is not completely unfolded but exhibits structural fluctuations on the time scale of secondary structure formation and loses its native conformation gradually when protein stability decreases. The redistribution of the ensemble of α-synuclein conformers may underlie toxic gain-of-function by fostering self-association and altered binding affinity to ligands and receptors.